Anika Therapeutics, Inc. Net Income Loss

• Anika Therapeutics, Inc. showed an increase of +80.7% in Net Income Loss from 2024 to 2025.
• This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Anika Therapeutics, Inc.'s Net Income Loss has declined by 395.0%.
• Historical annual values: Fiscal year 2025: -$10.88 million | Fiscal year 2024: -$56.39 million | Fiscal year 2023: -$82.67 million | Fiscal year 2022: -$14.86 million | Fiscal year 2021: $4.13 million | Fiscal year 2020: -$23.98 million | Fiscal year 2019: $27.19 million | Fiscal year 2018: $18.72 million | Fiscal year 2017: $31.82 million | Fiscal year 2016: $32.55 million | Fiscal year 2015: $30.76 million | Fiscal year 2014: $38.32 million | Fiscal year 2013: $20.58 million | Fiscal year 2012: $11.76 million | Fiscal year 2011: $8.47 million | Fiscal year 2010: $4.32 million | Fiscal year 2009: $3.69 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026